NAPWA, TAEP to Urge Congress to Implement Healthcare Reform, End Federal Bans Targeting HIV-Positive Americans at AIDSWatch 2012
April 19, 2012 08:00 ET
|
National Association of People with AIDS
WASHINGTON, DC--(Marketwire - Apr 19, 2012) - Today the National Association of People with AIDS (NAPWA) and the Treatment Access Expansion Project (TAEP) announces AIDSWatch 2012, the largest...
NAPWA's "Healthy Living Summit," Largest National Conference by and for People Living With HIV, to Convene in Dallas April 10 - 13
April 06, 2012 09:40 ET
|
National Association of People with AIDS
WASHINGTON, DC and DALLAS, TX--(Marketwire - Apr 6, 2012) - The National Association of People with AIDS (NAPWA) today announced that it will host the first annual National Healthy Living Summit...
Research Team Discovers Four-Fold Improvement in Ability to Restore Lymphatic Function With Adenovirally-Delivered VEGF-C Gene Therapy After Lymph Node Transplant Surgery Compared to the Surgery Alone
March 06, 2012 14:30 ET
|
Laurantis Pharma OY
VENTURA, CA--(Marketwire - Mar 6, 2012) - Lymphedema Awareness Day was established to support the needs of patients with lymphedema and to raise awareness for the need to develop new treatment...
With Final Review of Phase IIb Viral Load Data Completed, Researchers Confirm Statistically Significant Reduction of HIV Viral Load on Vacc-4x Compared to Placebo
February 15, 2012 08:00 ET
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - Feb 15, 2012) - Bionor Pharma (OSLO: BIONOR)
News Summary
Final review of phase IIb data confirms statistically significant 64%...
With Final Documentation Submitted for International Patent Applications, Bionor Sees Promise of Two Core Platform Technologies
January 23, 2012 08:00 ET
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - Jan 23, 2012) -
News Summary
Bionor Pharma ASA has previously submitted two international patent applications for the Company's...
Researchers Study Nasal Administration of Bionor Pharma's Therapeutic HIV Vaccine Vacc-4x Combined With Eurocine Vaccines' Endocine(TM) in Fully Enrolled Trial; New Treatment Option Would Offer Easier Treatment Access for HIV Patients Globally
January 04, 2012 08:00 ET
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - Jan 4, 2012) -
News Summary
Bionor Pharma's Vacc-4x is an investigational therapeutic HIV vaccine that has already shown in a...
Bionor Pharma's Universal Influenza Vaccine, Vacc-Flu, Targets Regions Shared by All Influenza A Strains; Reduces Serious Flu Symptoms by 25 Percent Over Standard Flu Vaccine in Animal Study
November 22, 2011 08:00 ET
|
Bionor Pharma
ARLINGTON, VA--(Marketwire - Nov 22, 2011) -
Summary of Findings
Bionor's Vacc-Flu could be "Universal," meaning that it could work on seasonal flu and also on...
VIRxSYS Issued U.S. Patents for Its Lentiviral Vector and SMaRT RNA Platforms
November 15, 2011 09:10 ET
|
VIRxSYS Corporation
GAITHERSBURG, MD--(Marketwire - Nov 15, 2011) - VIRxSYS Corporation, a Maryland-based biotechnology company, today announced that the United States Patent and Trademark Office has issued two...
NAPWA Announces New HIV Initiative to Combat Transmission Rates in the District of Columbia; New Program Will Target the Approximately 10,000 HIV Positive District Residents Currently Unaware of Their Status
September 27, 2011 12:00 ET
|
National Association of People with AIDS
WASHINGTON, DC--(Marketwire - Sep 27, 2011) - Frank Oldham Jr., President and CEO of the National Association of People With AIDS (NAPWA), today announced participation in a program that will use...
Lymfactin(TM):in on todettu merkittävästi lisäävän imusuonien kasvua eläintutkimuksessa; Tulokset nähdään ’tienä läpimurtoon’ rintasyöpäpotilailla, jotka hyötyisivät imusolmukesiirroista lymfedeeman vuoksi
September 23, 2011 10:23 ET
|
Laurantis Pharma
MALMO, SWEDEN--(Marketwire - Sep 23, 2011) -
Laurantis Pharma, yksityisomisteinen bioteknologiayhtiö, joka toimii Suomessa, ilmoitti tänään, että Lymfactin(TM),...